
Beacon Therapeutics completes enrollment in registrational Phase 2/3 VISTA trial of laru-zova for patients with XLRP
Topline data expected in H2 2026 LONDON and CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (“Beacon Therapeutics” or ”the Company”), a leading clinical-stage biotechnology company with a mission to save and restore …